Here Is What You Need to Know
New Pancreatic Cancer Drug 2026 — Daraxonrasib, Optune Pax, KRAS Mutation & Who Qualifies
The Cancer That Has Not Changed in 30 Years Just Changed
There is a brutal honesty that oncologists have had to deliver to pancreatic cancer patients for decades. We have chemotherapy. It is hard on you. It buys some time. Not much. Maybe a few months. For the majority of patients suffering from advanced disease, the talk starts to shift from how to cure the cancer or dramatically lengthen the patient’s life, to how to make the best of the time that remains.
Leanna Stokes was a part of one of those conversations at Memorial Sloan Kettering Cancer Center. She was diagnosed with pancreatic cancer and was not responding to standard treatment, and received information about a clinical trial for a new treatment. She enrolled. She took a pill — not an IV infusion, not a tough regimen of chemotherapy — a pill she took every day and began to get better in days. She was in good enough spirits to travel. To be present at family activities. To recover months of life she perhaps didn’t have.
The data is Leanna’s experience. And the numbers are remarkable.
In May 2026, the results from the Phase 3 RASolute 302 trial were released — and presented in a plenary session at the 2026 ASCO Annual Meeting, the highest-profile oncology conference in the world. The trial was carried out in patients with metastatic pancreatic cancer who had previously been treated. The outcome: median overall survival of 13.2 months with daraxonrasib compared with 6.7 months of standard chemotherapy, an almost doubling of survival with a 60% decrease in mortality.
This is no small accomplishment for a cancer that has not seen significant advances over 30 years. It’s a paradigm change.
2026 Pancreatic Cancer Breakthroughs
Daraxonrasib (RASolute 302 trial): Median overall survival 13.2 months vs 6.7 months on chemotherapy — 60% reduction in death risk — FDA expanded access approved in 2 days — ASCO 2026 plenary presentation. Optune Pax: First FDA-approved treatment for locally advanced pancreatic cancer in nearly 30 years — approved February 2026.
Table of Contents
Why Pancreatic Cancer Has Been So Hard to Treat
It’s important to realize that 2026 is different because it’s important to grasp why pancreatic cancer has been so resistant to treatment for so long. The simple answer is two words – KRAS mutation.
A gene like a gas peddle in a car that accelerates cell growth is called KRAS. Under normal conditions it triggers the growth of cells in a controlled manner — with the appropriate signals. When KRAS is mutated, it becomes stuck in the ‘on’ position. The cell grows and divided without any brakes. Cancer.
About 95% of all pancreatic cancers have a mutated version of a gene called KRAS. This is the most universal driver of all major cancers. For decades, KRAS was known as ‘undruggable’ – scientists could see what it was causing the problem but couldn’t find a molecule that would block it without also interfering with essential processes in healthy cells.
That is why targeted therapy has not yet caught up with pancreatic cancer, and why the revolution that has made lung, breast and melanoma a joy to treat over the last 20 years bypassed pancreatic cancer. EGFR inhibitors are drugs used for the treatment of lung cancer. Melanoma had BRAF inhibitors. With pancreatic cancer, there was chemotherapy called gemcitabine, developed in the 1990s, and little else.
In 2021, a KRAS inhibitor for the G12C mutation was approved for lung cancer. However, the G12C variant is not common in pancreatic cancer. Most pancreatic tumour mutations that were G12D, G12V, G12R were untargetable.
Until now.
What Is Daraxonrasib and How Does It Work?
Daraxonrasib, developed by Revolution Medicines, is a multiselective inhibitor of RAS – a completely new class of target-oriented therapy. Daraxonrasib is more radical than the earlier KRAS drugs, which tried to block the mutant protein from interfering with its work.
Dr. Won Jin Park, the principal investigator of the first-in-human clinical trial of the drug and author of the March 2026 paper in the New England Journal of Medicine, puts it like this: daraxonrasib is basically telling the body, “We don’t need the protein that the KRAS mutation made.” Does not affect the accelerator. It eradicates it completely.
This process, referred to as targeted protein degradation, is one of the most promising new areas of oncology research. It is applicable to KRAS in pancreatic cancer and targets more than one variant of the KRAS mutation: G12D, G12V, G12R, Q61X. That’s important because it is not a small group of pancreatic cancers that the drug could be useful in; it could be a wide range.
It is also an oral drug (a tablet that is taken by mouth every day) not an injection into a vein. This can make a huge difference for people who are already stressed out from the cancer treatment.
The Trial Results — The Numbers That Changed Everything
| Daraxonrasib | Standard Chemotherapy | |
| Median Overall Survival | 13.2 months | 6.7 months |
| Risk of Death Reduced By | 60% | Baseline |
| Disease Control Rate | 90% (first-line) | Lower |
| Response Rate | 58% (with chemo combo) | Lower |
| Side effects | Generally well tolerated | Significant toxicity |
| Route | Oral (daily tablet) | IV infusion |
The numbers below are based on a gold standard clinical evidence study, a random controlled trial known as the RASolute 302 Phase 3 trial. The patients who participated in this trial had at least one previous treatment failure. These were those who had the fewest options left. But, the drug almost doubled their survival time.
The FDA reacted more quickly than usual. On April 28, 2026, Revolution Medicines filed an expanded access application, requesting to provide daraxonrasib to eligible patients before the formal FDA approval application is submitted, and received a ‘safe to proceed’ letter in only 2 days. Surgeon and physician Marty Makary, who has personally treated cancer patients, said publicly: ‘Having treated many cancer patients with metastatic cancer myself, I am hopeful that today’s action will help enhance the lives of cancer patients who are suffering.
FDA Status of Daraxonrasib — May 2026
Breakthrough Therapy Designation: Granted June 2025 | Orphan Drug Designation: Granted | Commissioner’s National Priority Voucher: Granted October 2025 | Expanded Access Programme: Approved May 2026 (2-day turnaround) | New Drug Application: Planned for submission under Priority Voucher pathway | ASCO 2026: Plenary presentation of full Phase 3 data | Full FDA Approval: Expected 2026–2027
The Second Breakthrough — Optune Pax
While Daraxonrasib is making the most headlines, it’s not the only pancreatic cancer breakthrough of 2026. The FDA last month approved Optune Pax for locally advanced pancreatic cancer in February 2026. It is the first new treatment to get FDA approval for this indication in almost 30 years, and the designation is important.
Optune Pax is not a drug. It’s a portable medical device, which is worn around the abdomen, that produces Tumor Treating Fields (TTFields): alternating electric fields that disrupt processes cancer cells require for division and survival. They do not harm healthy cells, as they have different electrical properties.
Results of the Phase 3 PANOVA-3 trial demonstrated statistically significant improvement in overall survival and significant prolongation of time to progression of pain with OPTUNE Pax treatment when given in combination with standard chemotherapy of gemcitabine and nab-paclitaxel. It’s a ‘fundamentally different treatment’ that uses a ‘biophysical approach’, says Novocure CEO Frank Leonard, which takes aim at the ‘unique electrical properties of cancer cells’.
In Optune Pax, the indication is for locally advanced disease, while in daraxonrasib, the indication is for metastatic disease; these use entirely different mechanisms. Combined, these are a real paradigm shift in treatment for pancreatic cancer in 2026, which would have seemed impossible even two years ago.
Who Qualifies for These New Treatments?
Daraxonrasib — Current Availability
- Patients who have experienced progression after at least one line of treatment for metastatic pancreatic ductal adenocarcinoma (PDAC)
- Mutation testing for the gene KRAS is required — most patients with PDAC will qualify as most have a KRAS mutation (around 95%).
- Now available under the expanded access programme, available at major cancer centres (Memorial Sloan Kettering, MD Anderson, Dana-Farber, Mayo Clinic) or on Revolution Medicines’ website
- The drug is expected to be fully approved and commercially available by 2026-27.
- Also under study is the combination of Daraxonrasib and chemotherapy as initial treatment (earlier stage access may be expanded)
Optune Pax — Current Availability
- All pancreatic cancer patients with locally advanced disease – cancer that has spread beyond the pancreas but not to distant organs
- Used in conjunction with gemcitabine and nab-paclitaxel chemotherapy
- FDA approved — may be used by oncologists who are treating locally advanced disease.
- If you have been diagnosed with a locally advanced PDAC, discuss eligibility with your oncologist.
Frequently Asked Questions
Q: What is daraxonrasib and how does it work?
Daraxonrasib is a new class of targeted therapy, developed by Revolution Medicines, that causes the body to break down and eliminate the mutant KRAS protein which is responsible for the growth of pancreatic cancer cells. Daraxonrasib is different from previous KRAS drugs, which simply stop the protein from working, and it gets rid of the protein. It is taken orally every day and is active in several forms of KRAS mutations, such as G12D, G12V, G12R, and Q61X, which means that it can be used in most pancreatic cancers.
Q: What did the daraxonrasib trial results show?
Results from the Phase 3 RASolute 302 trial presented during ASCO 2026 indicated that daraxonrasib nearly doubled median overall survival in patients with previously treated metastatic pancreatic cancer, from 13.2 months with daraxonrasib to 6.7 months with standard chemotherapy. This is a 60% decrease in the likelihood of dying. When the drug was used as first-line treatment with chemotherapy, it achieved a 58% objective response rate and a 90% disease control rate.
Q: Is daraxonrasib FDA approved?
Daraxonrasib is currently FDA Breakthrough Therapy designated, FDA Orphan Drug designated and has been designated as a Commissioner’s National Priority Voucher programme candidate as of May 2026. In May 2026, FDA approved an expanded access programme, which will enable eligible patients outside clinical trials to access the drug. A formal New Drug Application (NDA) is being submitted under the Priority Voucher pathway. The Phase 3 RASolute 302 data is expected to be submitted for full approval in 2026 or 2027.
Q: What is Optune Pax for pancreatic cancer?
Optune Pax is a medical device to be worn that provides alternating electric fields (Tumor Treating Fields) that interfere with the division of cancer cells, but do not greatly impact healthy cells. In February 2026, FDA approved for locally advanced pancreatic cancer in combination with standard chemotherapy. The drug, which comes from the PANOVA-3 Phase 3 trial, is the first new FDA-approved locally advanced pancreatic cancer drug in nearly three decades.
Q: What is a KRAS mutation in pancreatic cancer?
KRAS is a gene that controls cell growth. It is permanently ‘switched on’ when it is mutated (in about 95% of all pancreatic cancers), leading to uncontrolled proliferation of cancer cells. There are different types of mutations in the gene called KRAS that are found in pancreatic cancer, with G12D, G12V, G12R and Q61H being the most common. For many years KRAS was thought to be undruggable. Daraxonrasib is the first molecule to target multiple variants of KRAS in the same molecule in the treatment of pancreatic cancer.
Conclusion — The Most Hopeful Moment in Decades
For an extremely long time, pancreatic cancer has been one of the most resistant diseases in medicine. The figures have been awful, the options few and the discussion problematic. This is changing.
Daraxonrasib is the most important progression in the treatment of metastatic pancreatic cancer in years. One pill doubles the survival rate, is effective against most of the mutations that fuel pancreatic cancer, and is overall very well tolerated — even giving patients such as Leanna Stokes the chance to attend family gatherings and travel while undergoing treatment for Stage 4 cancer. That’s no trivial matter. This is a paradigm change about receiving this diagnosis.
For patients with locally advanced disease, who have previously only received one of the same treatments that have been available for decades, optune Pax is a truly new treatment option that has proved to lengthen survival in a Phase 3 trial.
Talk to your oncologist about KRAS mutation testing and whether daraxonrasib is a treatment option for you or someone you love if they’ve been diagnosed with pancreatic cancer. Discuss Optune Pax with you if you have locally advanced disease. The choices are growing — and for the first time in many years — so is the hope.
Medical Disclaimer
This article is for informational purposes only. Always consult a qualified oncologist before making any cancer treatment decisions. Information about clinical trials and expanded access programmes changes rapidly — verify current eligibility with your healthcare team.